GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » EBIT

MYND Life Sciences (XCNQ:MYND) EBIT : C$-0.30 Mil (TTM As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences EBIT?

MYND Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Jul. 2024 was C$-0.34 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.30 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MYND Life Sciences's annualized ROC % for the quarter that ended in Jul. 2024 was -44.78%. MYND Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was -27,360.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MYND Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2024 was -3.91%.

MYND Life Sciences EBIT Historical Data

The historical data trend for MYND Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences EBIT Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
EBIT
-4.40 -3.03 -0.79

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 0.59 -0.33 -0.22 -0.34

Competitive Comparison of MYND Life Sciences's EBIT

For the Biotechnology subindustry, MYND Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MYND Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MYND Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MYND Life Sciences's EV-to-EBIT falls into.


MYND Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MYND Life Sciences  (XCNQ:MYND) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MYND Life Sciences's annualized ROC % for the quarter that ended in Jul. 2024 is calculated as:

ROC % (Q: Jul. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2024 ) + Invested Capital (Q: Jul. 2024 ))/ count )
=-1.368 * ( 1 - 0% )/( (3.005 + 3.105)/ 2 )
=-1.368/3.055
=-44.78 %

where

Invested Capital(Q: Apr. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.708 - 3.317 - ( 0.002 - max(0, 6.317 - 0.703+0.002))
=3.005

Invested Capital(Q: Jul. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.72 - 3.708 - ( 0 - max(0, 6.708 - 0.615+0))
=3.105

Note: The Operating Income data used here is four times the quarterly (Jul. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

MYND Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Apr. 2024  Q: Jul. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.368/( ( (0.005 + max(-2.616, 0)) + (0.005 + max(-3.095, 0)) )/ 2 )
=-1.368/( ( 0.005 + 0.005 )/ 2 )
=-1.368/0.005
=-27,360.00 %

where Working Capital is:

Working Capital(Q: Apr. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.69 + 0 + 0.011) - (3.317 + 0 + 0)
=-2.616

Working Capital(Q: Jul. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.604 + 0 + 0.009) - (3.708 + 0 + 0)
=-3.095

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MYND Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jul. 2024 )
=-0.304/7.781
=-3.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MYND Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » EBIT
Comparable Companies
XCNQ:ABRT XCNQ:ENBI XCNQ:HAVN TSXV:IBO XCNQ:GTTX XCNQ:WESA.X XCNQ:MOOD TSXV:BTI XCNQ:AGN XCNQ:CURE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
MYNDF:USA
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
Website
https://www.myndsciences.com
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.